Health Trials

Canagliflozin Targeting Vascular Inflammation

ConditionsDiabetes Type 2Coronary Artery Disease
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation

About this trial

CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.

Eligibility criteria

Qualifiers

1) Stable CAD (over 60 days post-myocardial infarction).

2) Diabetes

3) given informed consent.

Disqualifiers

severe LV dysfunction (EF<50%);

decompensated heart failure;

active infection (e.g. pneumonia, active skin infections, and on antibiotics);

active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, SLE, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate));

Trial design

Treatments tested in this trial

  • Canagliflozin
  • Placebo

Treatment groups

24 Participants
are divided into 2 treatment groups

Locations

1
University of Ottawa Heart InstituteK1Y 4W7, OttawaOntario, Canada

Sponsors and collaborators

Ottawa Heart Institute Research Corporation

Lead sponsor

Source ClinicalTrials.gov